The New York State Medical Marijuana Program

Guidance on Use of Vaping Products for Medical Marijuana Patients

The NYS Department of Health urges all New Yorkers to stop using vape products until the definitive cause of reported vaping-associated serious pulmonary (lung) illnesses nationwide can be better determined. Since the investigation into the illnesses began, there have been no reports of adverse events associated with approved products in the NYS Medical Marijuana Program related to the outbreak. Medical marijuana products are approved by the Department and rigorously tested for contaminants, pesticides and concentration of cannabinoids, including, but not limited to Tetrahydrocannabinol (THC) and Cannabidiol (CBD). However, out of an abundance of caution, we are also urging patients in the medical marijuana program to consult with their health care providers on potential alternatives to vaping products while the investigation continues.

For more information about vaping-associated illnesses, click here.

NEW! Provider Education Applications Being Accepted

Individuals or organizations that offer medical marijuana educational courses for health care providers and are interested in offering those courses through the NYS Medical Marijuana Program can find more information here.

Department of Financial Services (DFS) Guidance to Health Insurers Regarding Coverage for Office Visits Related to Medical Marijuana

The New York State Department of Financial Services (DFS) recently issued guidance to health insurers regarding coverage for office visits related to medical marijuana. The guidance from DFS may be accessed by clicking on the following link: http://www.dfs.ny.gov/about/press/pr1704121.htm.

The Department Announces Updates to the Medical Marijuana Program